Osteoporosis Drugs Market to cross USD
22,947.0 Millionby 2030
The global osteoporosis drugs market is witnessing growth and is projected to reach USD 22,947.0 million by 2030. The industry is propelled by growing healthcare investment, the high occurrence of osteoporosis, and the quick urbanization upsetting bone health.
On the basis of type, the bisphosphonates category dominated the market with the largest revenue share, and it is additionally projected to endure its supremacy in the future as well. This is mainly because bisphosphonates have confirmed effectiveness in reducing fracture danger at the spine, hip, and other non-vertebral emaciated sites, surge the existence rate, and reduce the substantial danger of morbidity.
Furthermore, the rising number of females in the post-menopausal stage and a rise in the occurrence of bone illnesses will further contribute to the requirement for these medications.
According to World Health Organisation data, due to the increased prevalence of diseases and a growing number of government initiatives both public and private, health expenditure is on the rise around the world. As a result, the health infrastructure improves, and access to care and diagnosis is becoming more accessible for different diseases.
To download a free sample copy of this research report@ https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample
In the osteoporosis drugs market, a category of RANK ligand inhibitors is forecast to increase at the highest compound annual growth rates over the forecast period. The identification of a receptor that is an activator of nuclear factor ligand, and as the key regulator of osteoclastic activity, has led to a new target for therapy. In early trials, the experimental highly selective antitank antibody denosumab has been shown to significantly reduce bone resorption.
The pharmacokinetics of the antibody are able to produce intramuscular injections spaced 6 months apart. RANKL inhibitors are a promising new way of treating osteoporosis and related conditions.
Osteoporosis results in decreased bone mass and significant loss of bone which increases fracture risk. It impacts individuals of both sexes and all races/ethnicities. For example, in the U.S. alone, there are about 2 million osteoporosis-linked fractures, and the price associated with osteoporosis each year is approximately USD 19 billion.
On the basis of application, the primary osteoporosis category accounts for a larger income share and it will also witness quicker development during the projection period. This is mainly because the mainstream cases that happened are of the primary type, which impacts females after menopause as a result of an unexpected decrease in estrogen production; the loss of bone structure because of the lack of testosterone in males; and the rising elderly populace in the U.S. and the EU.
Over the last years, North America's osteoporosis medicine market has been the largest source of revenue with around 45 %. This is due to the growing geriatric population, surging cases of obesity, increasing prevalence of lifestyle-associated diseases, and rising prevalence of osteoporosis, in the region.
Market Segmentation
The research offers market size of the global osteoporosis drugs market for the period 2017–2030.
Market Segmentation by Type
Bisphosphonates
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone Therapy
RANK Ligand Inhibitors
Others
Market Segmentation by Route of Administration
Oral
Injectable
Others
Market Segmentation by Application
Primary Osteoporosis
Secondary Osteoporosis
Market Segmentation by Region
North America Osteoporosis Market
o By type
o By route of administration
o By application
o By country – U.S. and Canada
Europe Osteoporosis Drugs Market
o By type
o By route of administration
o By application
o By country – France, Germany, Italy, Spain, U.K., and Rest of Europe
Asia-Pacific (APAC) Osteoporosis Drugs Market
o By type
o By route of administration
o By application
o By country – China, India, Japan, South Korea, Australia, and Rest of APAC
Latin America (LATAM) Osteoporosis Drugs Market
o By type
o By route of administration
o By application
o By country – Brazil, Mexico, and Rest of LATAM
Middle East and Africa (MEA) Osteoporosis Drugs Market
o By type
o By route of administration
o By application
o By country – Saudi Arabia, South Africa, and Rest of MEA
Disclaimer:
P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations.P&SIntelligenceis notresponsible foranyincorrectdata providedbythekeyindustryplayers of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse anyproduct, service, or vendor depicted in its research publications.
All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected bycopyright. Undernocircumstancecanthese bereproduced in anyformwithoutpriorwrittenagreement oftheir owners.
An order for market research report is intended for internal use of the companyonlyand not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd.